Abstract Number: 0052 • ACR Convergence 2021
HLA-B27 Is Associated with Altered Mucosal IgA Response to Oral and Fecal Microbiota in Patients with Axial Spondyloarthritis
Background/Purpose: Axial spondyloarthritis (AxSpA) is immune-mediated inflammatory arthritis, which affects the sacroiliac and spinal joints, and is associated with gut inflammation. Disease pathogenesis is associated…Abstract Number: 0358 • ACR Convergence 2021
Work Participation in Patients with Axial Spondyloarthritis in Germany: Results from a Multicenter, Observational Survey
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory condition often associated with impaired working participation1 not only translating to devastating outcomes for patients (pts) but…Abstract Number: 0385 • ACR Convergence 2021
The Diagnostic Utility of Serum interleukin-22 in Patients with Suspected Axial Spondyloarthritis
Background/Purpose: There is an unmet need for a reliable biomarker for the diagnosis and differentiation of AxSpA from its multiple mimickers. Serum levels of IL-22,…Abstract Number: 0620 • ACR Convergence 2021
Is There a Difference in Disease Activity Between Genders in Axial Spondyloarthritis? 6-year Longitudinal Data from a Large National Cohort
Background/Purpose: Recent data suggest differences between men and women with axial spondyloarthritis (axSpA), in terms of disease activity, disease progression and treatment response [1-3]. Overall,…Abstract Number: 0739 • ACR Convergence 2021
Contextual Factors Should Complete the Assessment of Functioning in Patients with Axial Spondyloarthritis (axSpA)
Background/Purpose: Functioning of axSpA patients (pat.) is influenced by many factors, but how contextual factors influence functioning isn’t well studied. According to the International Classification…Abstract Number: 0745 • ACR Convergence 2021
Patient-reported Outcomes and Safety Measures in Patients with Rheumatic Diseases Who Switched from Reference or Other Biosimilar Etanercept to Biosimilar Etanercept GP2015 and in Biologic-naïve Patients Starting a Treatment with GP2015: 12-month Interim Analysis from a Real-world Study
Background/Purpose: GP2015 is a biosimilar of etanercept (ETN). COMPACT is an ongoing, non-interventional study, evaluating the effectiveness, safety, and quality of life with GP2015 treatment…Abstract Number: 0906 • ACR Convergence 2021
Measurement of Vertebral Hounsfield Units in Low Dose Computed Tomography – a Reliable Methodology for Assessing Bone Mineral Density at the Vertebral Level in Patients with Radiographic Axial Spondyloarthritis
Background/Purpose: Bone loss paradoxically coexists with bone formation in radiographic axial spondyloarthritis (r-axSpA). Assessing bone mineral density (BMD) in r-axSpA poses challenges, namely because of…Abstract Number: 0924 • ACR Convergence 2021
Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondylitis: 2-Year Results from a Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension
Background/Purpose: The objective of this long-term analysis of the SELECT-AXIS 1 study was to report safety and efficacy of upadacitinib (UPA) in active AS through…Abstract Number: 1828 • ACR Convergence 2021
Safety Profile of Ixekizumab for the Treatment of Psoriatic Arthritis and Axial Spondyloarthritis up to 3 Years: An Updated Integrated Safety Analysis
Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets IL-17A approved for the treatment of psoriasis, psoriatic arthritis (PsA), active ankylosing spondylitis (AS)…Abstract Number: L21 • 2019 ACR/ARP Annual Meeting
Secukinumab 150 mg Significantly Improved Signs and Symptoms of Non-radiographic Axial Spondyloarthritis: Results from a Phase 3 Double-blind, Randomized, Placebo-controlled Study
Background/Purpose: Non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS) are considered part of the spectrum of axSpA. Patients (pts) are classified as nr-axSpA due to…Abstract Number: 579 • 2019 ACR/ARP Annual Meeting
Is There an Impact of Uveitis, Psoriasis and Inflammatory Bowel Disease on Musculoskeletal Disease Activity and Function in Axial Spondyloarthritis?
Background/Purpose: Uveitis, psoriasis and inflammatory bowel disease (IBD) are common in axial spondyloarthritis (axSpA) but data on their impact on activity of musculoskeletal manifestations and…Abstract Number: 609 • 2019 ACR/ARP Annual Meeting
Baseline Characteristics and Natural History of Radiographic versus Non-radiographic Axial Spondyloarthritis: 5 Years Follow-up of the Desir Cohort
Background/Purpose: There is still a debate concerning the concept of non-radiographic (nr-axSpA) axial Spondyloarthritis (e.g. to consider it as a distinct entity from r-axSpA (Ankylosing…Abstract Number: 935 • 2019 ACR/ARP Annual Meeting
Reduction of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis Following 1 Year of Treatment with Certolizumab Pegol: 48-Week Interim Results from a 96-Week Open-Label Study
Background/Purpose: Acute anterior uveitis (AAU), inflammation of the anterior uveal tract, is the most common extraarticular manifestation in patients (pts) with axial spondyloarthritis (axSpA), reported…Abstract Number: 1500 • 2019 ACR/ARP Annual Meeting
Effectiveness of Switching Between TNF Inhibitors in Patients with Axial Spondyloarthritis: Is the Reason to Switch Relevant?
Background/Purpose: Over the last years, and mostly due to lack of alternatives, it has been common practice to start a second TNF inhibitor (TNFi) in…Abstract Number: 1820 • 2019 ACR/ARP Annual Meeting
Clinically Relevant Deficits in Performance Tests in Patients with Axial Spondyloarthritis(axSpA) – Collecting Questionnaires Is Insufficient
Background/Purpose: Physical function in axial spondyloarthritis (axSpA) usually assessed by the BASFI questionnaire is an established core domain of that disease. There is evidence that…
- 1
- 2
- 3
- …
- 16
- Next Page »